Sesquiterpenes and isocoumarins from Diaporthe phaseolorum and their antibacterial activity against Pseudomonas syringae pv. actinidiae

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-08-18 DOI:10.1016/j.phytol.2025.103033

Qing-Shu Chen , Tian Jin , Jiao-Xian Du , Shan-Shan Huang , Zheng-Hong Pan , Juan He

引用次数: 0

Abstract

In order to search for antibacterial agents against Pseudomonas syringae pv. actinidiae (Psa), a bacterial causing kiwi cancer disease, three previously undescribed eremophilane-type sesquiterpenes, phaseolumins A–C (1–3), together with four isocoumarins (4–7) have been isolated from the fungus Diaporthe phaseolorum. Their chemical structures including absolute configurations were determined according to spectroscopic analysis (1D, ²D NMR and HRESIMS), single-crystal X-ray diffraction and ECD calculations. Compounds 1, 3, and 7 exhibited anti-Psa activity with minimum inhibitory concentration (MIC) values ranging from 64 to 128 μg/mL.

查看原文本刊更多论文

皂荚的倍半萜和异香豆素及其对丁香假单胞菌的抑菌活性。actinidiae

目的寻找抗丁香假单胞菌的抗菌药物。从真菌Diaporthe phaseolorum中分离出了三种先前未被描述过的辣椒碱型倍半萜，phaseolumins a - c（1-3）和四种异香豆素（4-7）。通过光谱分析（1D， 2D NMR和hremsims），单晶x射线衍射和ECD计算确定了它们的化学结构，包括绝对构型。化合物1、3和7具有抗psa活性，最小抑制浓度（MIC）在64 ~ 128 μg/mL之间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.